Molecular Oncology
Volume 2, Issue 1 , Pages 70-80, June 2008

Mutant p53 targeting by the low molecular weight compound STIMA-1

  • Nicole Zache

      Affiliations

    • Karolinska Institutet, Department of Oncology-Pathology, Cancer Center Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden
  • ,
  • Jeremy M.R. Lambert

      Affiliations

    • Karolinska Institutet, Department of Oncology-Pathology, Cancer Center Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden
    • International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France
  • ,
  • Nina Rökaeus

      Affiliations

    • Karolinska Institutet, Department of Oncology-Pathology, Cancer Center Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden
  • ,
  • Jinfeng Shen

      Affiliations

    • Karolinska Institutet, Department of Oncology-Pathology, Cancer Center Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden
  • ,
  • Pierre Hainaut

      Affiliations

    • International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France
  • ,
  • Jan Bergman

      Affiliations

    • Karolinska Institutet, Department of Biosciences, Novum, Huddinge, Sweden
  • ,
  • Klas G. Wiman

      Affiliations

    • Karolinska Institutet, Department of Oncology-Pathology, Cancer Center Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden
    • Corresponding Author InformationCorresponding author. Cancer Center Karolinska (CCK), R8:04, Karolinska University Hospital, 171 76 Stockholm, Sweden. Tel.: +48 8 5177 9342; fax: +46 8 321 047.
  • ,
  • Vladimir J.N. Bykov

      Affiliations

    • Karolinska Institutet, Department of Oncology-Pathology, Cancer Center Karolinska (CCK), Karolinska University Hospital, Stockholm, Sweden

Received 28 October 2007; received in revised form 25 February 2008; accepted 28 February 2008. published online 07 April 2008.

Abstract 

Reactivation of mutant p53 in human tumor cells should induce cell death by apoptosis and thus eliminate the tumor. Several small molecules that reactivate mutant p53 have been identified. Here we show that STIMA-1, a low molecular weight compound with some structural similarities to the previously identified molecule CP-31398, can stimulate mutant p53 DNA binding in vitro and induce expression of p53 target proteins and trigger apoptosis in mutant p53-expressing human tumor cells. Human diploid fibroblasts are significantly more resistant to STIMA-1 than mutant or wild type p53-carrying tumor cells. STIMA-1 may provide new insights into possible mechanisms of mutant p53 reactivation and thus facilitate the development of novel anticancer drugs that target mutant p53-carrying tumors.

Keywords: Mutant p53 reactivation, STIMA-1, CP-31398, Apoptosis, Cancer therapy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1574-7891(08)00028-8

doi:10.1016/j.molonc.2008.02.004

Molecular Oncology
Volume 2, Issue 1 , Pages 70-80, June 2008